Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GlycoNex's dividends per share for the
three
months ended in Dec. 2025 was NT$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.00. Its Dividend Payout Ratio for the
three
months ended in Dec. 2025 was 0.00. As of today, GlycoNex's Dividend Yield % is 0.00%.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlycoNex Dividends per Share Related Terms
GlycoNex Dividends per Share Historical Data
* Premium members only.
The historical data trend for GlycoNex's Dividends per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4168 vs VRTX, REGN, RVMD: Dividends per Share Comparison
For the Biotechnology subindustry, GlycoNex's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlycoNex Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GlycoNex's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where GlycoNex's Dividend Yield % falls into.
GlycoNex (ROCO:4168) has a Dividends per Share of NT$0.00 as of Dec. 2025. Dividends per share represents the per-share amount paid as dividends. View historical data on GlycoNex and its competitors.
Is GlycoNex's Dividends per Share too high?
GlycoNex's current Dividends per Share is NT$0.00. Overall, GlycoNex has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlycoNex's Dividends per Share compare to VRTX and REGN?
GlycoNex's Dividends per Share of NT$0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on GlycoNex and its competitors. GlycoNex's current Dividends per Share is NT$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlycoNex stock overvalued right now?
Based on GuruFocus' analysis, GlycoNex (ROCO:4168) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$76.27, compared to a current price of NT$22.25 — trading 70.8% below its estimated fair value. The current Dividends per Share is NT$0.00. GlycoNex's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For GlycoNex (ROCO:4168), the current Dividends per Share is NT$0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlycoNex (ROCO:4168) Overvalued in 2026?
Based on GuruFocus' analysis, GlycoNex stock appears to be undervalued.
The current stock price of NT$22.25 is trading 70.8% below its estimated GF Value™ of NT$76.27.
GuruFocus considers GlycoNex to be Significantly Undervalued.
Key valuation signals for ROCO:4168:
Dividends per Share: NT$0.00
GF Value™: NT$76.27 vs. price of NT$22.25 (70.8% below fair value)
No single metric tells the full story. See the ROCO:4168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlycoNex Inc is a Taiwan-based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The other services provided by the firm include functional evaluation, antibody research, and antibody engineering. It has two reportable segments: antibody new drug, which derives maximum revenue, and exclusive investment. Geographically, the group derives maximum revenue from Taiwan and the rest from Japan.
57GF Score
Get the complete analysis for ROCO:4168
Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4168 has been successfully added to your 
